UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 121

Sortiert nach

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

Journal of clinical oncology, 2013-10, Vol.31 (29), p.3688-3695

2013

Volltextzugriff (PDF)

Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery

Molecular cancer therapeutics, 2006-08, Vol.5 (8), p.1909-1917

2006

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Journal of clinical oncology, 2010-06, Vol.28 (18), p.3015-3022

2010

Volltextzugriff (PDF)

Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era

British journal of haematology, 2016-03, Vol.172 (5), p.724-734

2016

Volltextzugriff (PDF)

Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors

Clinical cancer research, 2008-08, Vol.14 (16), p.5090-5098

2008

Volltextzugriff (PDF)

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

The Lancet (British edition), 2023-05, Vol.401 (10390), p.1773-1785

2023

Volltextzugriff (PDF)

Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma

Advances in Hematology, 2011, Vol.2011, p.736261-10

2011

Volltextzugriff (PDF)

Improving Outcomes for Patients with Diffuse Large B‐cell Lymphoma

CA: a cancer journal for clinicians, 2010-11, Vol.60 (6), p.393-408

2010

Volltextzugriff (PDF)

Monitoring Changes in Physical, Chemical and Biological Properties of Soil Due to Long Term Fertilizer Effect

International journal of current microbiology and applied sciences, 2018-04, Vol.7 (4), p.2307-2311

2018

Volltextzugriff (PDF)

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Blood, 2010-04, Vol.115 (13), p.2578-2585

2010

Volltextzugriff (PDF)

Racial differences in the presentation and outcomes of diffuse large B‐cell lymphoma in the United States

Cancer, 2011-06, Vol.117 (11), p.2530-2540

2011

Volltextzugriff (PDF)

Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1127-TPS1127

2022

Volltextzugriff (PDF)

Effect of legume intercropping and foliar spray of zinc and iron on maize

The pharma innovation, 2023-01, Vol.12 (1), p.247-249

2023

Volltextzugriff (PDF)

Development of the Lymphoma Enterprise Architecture Database: A caBIG(TM) Silver Level Compliant System

Cancer informatics, 2009-01, Vol.2009 (Semantic Technologies Special Issue (2009)), p.45-64

2009

Volltextzugriff (PDF)

Novel agents for diffuse large B-cell lymphoma

Expert opinion on investigational drugs, 2011-05, Vol.20 (5), p.669-680

2011

Volltextzugriff (PDF)

Elemental accumulation in mango (Mangifera indica L.) as a function of maturity stage and variety

Journal of plant nutrition, 2017-08, Vol.40 (13), p.1805-1815

2017

Volltextzugriff (PDF)

Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD1-06-PD1-06

2020

Volltextzugriff (PDF)

SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS1110-TPS1110

2019

Volltextzugriff (PDF)

The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States

Cancer, 2014-06, Vol.120 (12), p.1830-1837

2014

Volltextzugriff (PDF)

Managing Nitrogen Requirements through Foliar Application of Nitrogen in Mustard (Brassica juncea L. Czernj. and Cosson.)

International journal of current microbiology and applied sciences, 2018-04, Vol.7 (4), p.3761-3768

2018

Volltextzugriff (PDF)

A curious ulcer on the pinna: rhinosporidiosis at an unusual place

International journal of dermatology, 2015-07, Vol.54 (7), p.e277-e279

2015

Volltextzugriff (PDF)

Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States

Clinical lymphoma, myeloma and leukemia, 2011-12, Vol.11 (6), p.498-506

2011

Volltextzugriff (PDF)

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

British journal of haematology, 2015-11, Vol.171 (4), p.539-546

2015

Volltextzugriff (PDF)

Examining racial differences in diffuse large B-cell lymphoma presentation and survival

Leukemia & lymphoma, 2013-02, Vol.54 (2), p.268-276

2013

Volltextzugriff (PDF)

Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States

Leukemia & lymphoma, 2015-05, Vol.56 (5), p.1295-1302

2015

Volltextzugriff (PDF)

1 – 25 von 121

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(117)

Publikationsform

Sprache

Englisch
(120)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(47)
Life Sciences & Biomedicine
(46)
Humans
(40)
Male
(25)
Middle Aged
(24)
Oncology
(23)
Female
(22)
Adult
(20)
Aged
(18)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Hematology
(13)
Treatment Outcome
(12)
Young Adult
(11)
Aged, 80 And Over
(10)
Chemotherapy
(9)
Hematology, Oncology And Palliative Medicine
(8)
Biological And Medical Sciences
(7)
Immunotherapy
(7)
India
(7)
Medical Sciences
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era

Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma

Improving Outcomes for Patients with Diffuse Large B‐cell Lymphoma

Monitoring Changes in Physical, Chemical and Biological Properties of Soil Due to Long Term Fertilizer Effect

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Racial differences in the presentation and outcomes of diffuse large B‐cell lymphoma in the United States

Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)

Effect of legume intercropping and foliar spray of zinc and iron on maize

Development of the Lymphoma Enterprise Architecture Database: A caBIG(TM) Silver Level Compliant System

Novel agents for diffuse large B-cell lymphoma

Elemental accumulation in mango (Mangifera indica L.) as a function of maturity stage and variety

Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer

The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States

Managing Nitrogen Requirements through Foliar Application of Nitrogen in Mustard (Brassica juncea L. Czernj. and Cosson.)

A curious ulcer on the pinna: rhinosporidiosis at an unusual place

Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

Examining racial differences in diffuse large B-cell lymphoma presentation and survival

Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States

Suchergebnisse filtern